Founded in 1971, Bachem Holding AG has grown into a global leader in peptide synthesis and complex organic compounds. The company operates primarily as a CDMO, partnering with pharmaceutical and biotech firms to design, develop, and produce active pharmaceutical ingredients (APIs) used in treatments for diseases like diabetes, cancer, and obesity. Bachem's business spans custom manufacturing for clinical development, commercial-scale API production, and the supply of research-grade biochemicals. Headquartered in Bubendorf, Switzerland, the company maintains a significant geographic footprint with production facilities in Switzerland, the United States, and the United Kingdom, alongside sales offices in Asia and Europe. By focusing exclusively on the specialized niche of peptides and oligonucleotides, Bachem has established a strong competitive position as a critical manufacturing partner to the life sciences sector.
